Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 11/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521594 | 0.90 | NAMPT (0.47) | LIPENAMPTHRH3EPHX2 | |
| SCHEMBL6523694 | 0.89 | LIPE (0.43) | LIPELIPGHSD11B1HRH3EPHX2 | |
| SCHEMBL6525990 | 0.89 | NAMPT (0.46) | LIPENAMPTHRH3 | |
| SCHEMBL6523469 | 0.88 | MMP1 (0.49) | LIPENAMPTHRH3ENPP2 | |
| SCHEMBL6518433 | 0.85 | EPHX2 (0.48) | LIPELIPGNAMPTEPHX2 | |
| SCHEMBL6520332 | 0.85 | DPP4 (0.43) | LIPENAMPTHRH3 | |
| SCHEMBL6521945 | 0.85 | HRH3 (0.44) | LIPENAMPTHRH3 | |
| SCHEMBL6521607 | 0.85 | LIPE (0.40) | LIPENAMPTEPHX2 | |
| SCHEMBL6525322 | 0.85 | P2RX3 (0.39) | LIPENAMPTHRH3 | |
| SCHEMBL6523919 | 0.83 | EPHX2 (0.48) | LIPENAMPTHRH3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | LIPE 4566/4885LIPG 2536/4885HSD11B1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.